The safety and efficacy of tyrosine kinase inhibitors and programmed cell death protein- 1 inhibitors combined with HAIC/TACE in the treatment of recurrent unresectable hepatocellular carcinoma

Table 4 Multivariate Analysis Associated with Progression-free Survival

Variables	Multivariate Analysis		Multivariate Analysis
Variables	HR (95% CI)	p-value	HR (95% CI)	p-value
AFP ≥ 400 ng/mL	2.55(1.19–5.47)	0.016	4.18(1.71–10.18)	0.002
PT	1.33(1.02–1.75)	0.036	1.30(1.03–1.65)	0.029
Time to recurrence after surgery ≥ 2	0.81(0.33–2.00)	0.644	0.99(0.43–2.27)	0.984
Tumor differentiation (L/M/H)	1.60(1.05–2.43)	0.027	1.56(1.06–2.28)	0.024
Satellite nodule	1.09(0.52–2.32)	0.813	0.47(0.16–1.37)	0.166
HTP vs TACE	0.29(0.15–0.55)	< 0.001	-	-
TTP vs TACE	-	-	0.27(0.13–0.56)	< 0.001

AFP alpha-fetoprotein, PT prothrombin time, HTP hepatic arterial infusion chemotherapy combined with tyrosine kinase inhibitors and programmed cell death protein- 1 inhibitors, TTP transarterial chemoembolization combined with tyrosine kinase inhibitors and programmed cell death protein- 1 inhibitors, TACE transarterial chemoembolization, HR hazard ratio, CI indicates confidence interval

ISSN: 1471-2407